Known targets — ChEMBL curated mechanism
CHRNA7HTR3AHTR3BHTR3CHTR3DHTR3E
The experimentally established mechanism targets of Facinicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 5/20 | 1.00 |
| ▸ | HTR3A known ✓ | P46098 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.59 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.53 |
| ▸ | CDK2 | P24941 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.53 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Facinicline SCHEMBL29749748 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL29365997 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL45698 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL260422 | 1.00 | CHRNA7 (1.00) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL260915 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL40976 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL29379716 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| Facinicline SCHEMBL261885 | 0.99 | CHRNA7 (0.98) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| SCHEMBL4618556 | 0.87 | CHRNA7 (0.77) | CHRNA7HTR3ANPC1RAB9AUSP30 | |
| SCHEMBL492170 | 0.87 | CHRNA7 (0.77) | CHRNA7HTR3ANPC1RAB9AUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | claimed |
| EP-2945633-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| EP-2945637-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| EP-2945626-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | Novartis AG (CH) | 2015-11-25 | — | — | EP | claimed |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS PHARMA AG (CH) | 2015-11-05 | — | — | US | claimed |
| WO-2014111837-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| WO-2014111751-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| WO-2014111838-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | claimed |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | claimed |
| CN-103260619-A | Treatment of cognitive disorders using certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors | ENVIVO PHARMACEUTICALS INC | 2013-08-21 | — | — | CN | claimed |
| EP-2598135-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | Koenig, Gerhard (US) | 2013-06-05 | — | — | EP | claimed |
| EP-1543000-B1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2013-03-06 | — | — | EP | claimed |
| US-8252811-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-08-28 | — | — | US | claimed |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2012-04-26 | — | — | US | claimed |
| WO-2012015749-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | claimed |
| WO-2012000925-A1 | PREPARATION OF N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | claimed |
| US-7429664-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | claimed |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-07-24 | — | — | US | claimed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | claimed |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2025-02-04 | — | — | US | disclosed |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2022-10-06 | — | — | US | disclosed |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2022-07-07 | — | — | US | disclosed |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | NOVARTIS AG (CH) | 2022-04-26 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| EP-2945633-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| EP-2945637-B1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2021-03-10 | — | — | EP | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| US-20170348294-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2017-12-07 | — | — | US | disclosed |
| EP-2931315-B1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828642-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2017-11-28 | — | — | US | disclosed |
| EP-2945633-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| EP-2945626-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | Novartis AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| EP-2945637-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | Novartis AG (CH) | 2015-11-25 | — | — | EP | disclosed |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS PHARMA AG (CH) | 2015-11-05 | — | — | US | disclosed |
| EP-2931315-A2 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | Novartis AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20150275303-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2768507-A2 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | Novartis AG (CH) | 2014-08-27 | — | — | EP | disclosed |
| US-20140228398-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2014-08-14 | — | — | US | disclosed |
| WO-2014111751-A1 | USE OF ALPHA 7 NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF NARCOLEPSY | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014111837-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| WO-2014111838-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2014-07-24 | — | — | WO | disclosed |
| US-20140171448-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| WO-2014091388-A2 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2014-06-19 | — | — | WO | disclosed |
| US-20140155429-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2706854-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE | Envivo Pharmaceuticals, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2685977-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | Novartis AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| CN-103260619-A | Treatment of cognitive disorders using certain alpha-7 nicotinic acid receptor agonists in combination with acetylcholinesterase inhibitors | ENVIVO PHARMACEUTICALS INC | 2013-08-21 | — | — | CN | disclosed |
| EP-2598135-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | Koenig, Gerhard (US) | 2013-06-05 | — | — | EP | disclosed |
| WO-2013057687-A2 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| EP-1543000-B1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | MEMORY PHARM CORP (US) | 2013-03-06 | — | — | EP | disclosed |
| EP-2523939-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYCLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| EP-2523939-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYCLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| WO-2012154710-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH NICOTINE | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| WO-2012127393-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2012-09-27 | — | — | WO | disclosed |
| US-8273891-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-25 | — | — | US | disclosed |
| US-8263619-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-09-11 | — | — | US | disclosed |
| US-8252811-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252811-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-08-28 | — | — | US | disclosed |
| US-8242276-B2 | Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt | HOFFMANN-LA ROCHE INC. (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242276-B2 | Methods for the preparation of N-(S)-1-azabicyclo[2.2.2]oct-3-yl-1H-indazole-3-carboxamide hydrochloride salt | HOFFMANN-LA ROCHE INC. (US) | 2012-08-14 | — | — | US | disclosed |
| EP-2480228-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | Novartis AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG | 2012-07-05 | — | — | US | disclosed |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE (US) | 2012-04-26 | — | — | US | disclosed |
| US-8134003-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-8134003-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| WO-2012015749-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| WO-2012015749-A1 | TREATMENT OF COGNITIVE DISORDERS WITH CERTAIN ALPHA-7 NICOTINIC ACID RECEPTOR AGONISTS IN COMBINATION WITH ACETYLCHOLINESTERASE INHIBITORS | ENVIVO PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-8106066-B2 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2012-01-31 | — | — | US | disclosed |
| WO-2012000925-A1 | PREPARATION OF N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000925-A1 | PREPARATION OF N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| WO-2012000925-A1 | PREPARATION OF N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-05 | — | — | WO | disclosed |
| US-20120004412-A1 | METHODS FOR THE PREPARATION OF N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | ROCHE CAROLINA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20120004412-A1 | METHODS FOR THE PREPARATION OF N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | ROCHE CAROLINA INC. | 2012-01-05 | — | — | US | disclosed |
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | XIE WENGE (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110212957-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-09-01 | — | — | US | disclosed |
| US-20110212957-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2011-09-01 | — | — | US | disclosed |
| WO-2011086031-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYCLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011086031-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYCLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20110172428-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | ROCHE CAROLINA INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172428-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | ROCHE CAROLINA INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172428-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | ROCHE CAROLINA INC. | 2011-07-14 | — | — | US | disclosed |
| US-7943773-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943773-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943773-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2305675-A1 | Indazoles, Benzothiazoles, and Benzoisothiazoles, and preparation and uses thereof | Memory Pharmaceuticals Corporation (US) | 2011-04-06 | — | — | EP | disclosed |
| WO-2011036167-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2011-03-31 | — | — | WO | disclosed |
| US-20100137288-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | SCHUMACHER RICHARD | 2010-06-03 | — | — | US | disclosed |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2010-04-29 | — | — | US | disclosed |
| US-20090209579-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-08-20 | — | — | US | disclosed |
| US-20090209579-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-08-20 | — | — | US | disclosed |
| US-20090209579-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2009-08-20 | — | — | US | disclosed |
| US-7429664-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429664-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429664-B2 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-07-24 | — | — | US | disclosed |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-07-24 | — | — | US | disclosed |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-07-24 | — | — | US | disclosed |
| EP-1940833-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | Memory Pharmaceuticals Corporation (US) | 2008-07-09 | — | — | EP | disclosed |
| US-20080154037-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-06-26 | — | — | US | disclosed |
| US-20080154037-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-06-26 | — | — | US | disclosed |
| US-20080154037-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | XIE WENGE | 2008-06-26 | — | — | US | disclosed |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2007-04-05 | — | — | US | disclosed |
| WO-2007038367-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | disclosed |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | MEMORY PHARMACEUTICALS CORPORATION | 2004-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (28 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172428-A1 | METHODS FOR THE PREPARATION OF INDAZOLE-3-CARBOXYLIC ACID AND N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | CHRNA7, CHRNA3, CHRNA5 | CHRNA7 1/4885HTR3A 76/4885NPC1 718/4885 |
| US-20150275303-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885HTR3A 112/4885NPC1 2134/4885 |
| US-20100137288-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, PYRAZOLOPYRIDINES, ISOTHIAZOLOPYRIDINES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885HTR3A 438/4885NPC1 418/4885 |
| US-11311525-B2 | Use of alpha 7 nicotinic acetylcholine receptor agonists | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885HTR3A 137/4885NPC1 3268/4885 |
| US-20120101094-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885NPC1 1336/4885 |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885HTR3A 112/4885NPC1 2134/4885 |
| US-20040132790-A1 | Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof | CHRNA5, CHRNA7, CHRNA3 | CHRNA7 2/4885HTR3A 166/4885NPC1 1448/4885 |
| US-20170348294-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885HTR3A 137/4885NPC1 3268/4885 |
| US-20140171448-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNG, CHRNA6 | CHRNA7 1/4885HTR3A 94/4885NPC1 3640/4885 |
| US-20140228398-A1 | COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE | CHRNA5, GRM5, CHRNA7 | CHRNA7 3/4885HTR3A 225/4885NPC1 3026/4885 |
| US-20110319407-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USE THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 352/4885NPC1 518/4885 |
| US-20090209579-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885NPC1 1336/4885 |
| US-20100105677-A1 | INDAZOLES, BENZOTHIAZOLES, BENZOISOTHIAZOLES, BENZISOXAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 367/4885NPC1 504/4885 |
| US-12215387-B2 | Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885HTR3A 131/4885NPC1 2105/4885 |
| US-20120172346-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3A 151/4885NPC1 2627/4885 |
| US-20130225560-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Acetylcholinesterase Inhibitors | CHRNA7, CHRNA6, CHRNA2 | CHRNA7 1/4885HTR3A 193/4885NPC1 802/4885 |
| US-20220211679-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA4 | CHRNA7 1/4885HTR3A 151/4885NPC1 638/4885 |
| US-20220316011-A1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885HTR3A 131/4885NPC1 2105/4885 |
| US-20080154037-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885NPC1 1336/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3A 151/4885NPC1 2627/4885 |
| US-20110212957-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885NPC1 1336/4885 |
| US-20080176890-A1 | INDAZOLES, BENZOTHIAZOLES, AND BENZOISOTHIAZOLES, AND PREPARATION AND USES THEREOF | CHRNA7, CHRNA5, CHRNA3 | CHRNA7 1/4885HTR3A 152/4885NPC1 1336/4885 |
| US-20140155429-A1 | Treatment of Cognitive Disorders with Certain Alpha-7 Nicotinic Acid Receptor Agonists in Combination with Nicotine | CHRNA7, CHRNA10, CHRNA5 | CHRNA7 1/4885HTR3A 112/4885NPC1 1113/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | CHRNA7 1/4885HTR3A 112/4885NPC1 2134/4885 |
| US-20070078147-A1 | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof | CHRNA7, CHRNA5, CHRNA2 | CHRNA7 1/4885HTR3A 438/4885NPC1 418/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3A 151/4885NPC1 2627/4885 |
| US-20150313884-A1 | USE OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS | CHRNA7, CHRNA1, CHRNA5 | CHRNA7 1/4885HTR3A 137/4885NPC1 3268/4885 |
| US-20120004412-A1 | METHODS FOR THE PREPARATION OF N-(S)-1-AZABICYCLO[2.2.2]OCT-3-YL-1H-INDAZOLE-3-CARBOXAMIDE HYDROCHLORIDE SALT | CHRNA7, CHRNA2, CHRNA5 | CHRNA7 1/4885HTR3A 143/4885NPC1 510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.